dc.creator | Rojas, Ángela | es |
dc.creator | Lara-Romero, Carmen | es |
dc.creator | Muñoz Hernández, Rocío | es |
dc.creator | Gato, Sheila | es |
dc.creator | Ampuero Herrojo, Javier | es |
dc.creator | Romero Gómez, Manuel | es |
dc.date.accessioned | 2023-10-26T15:56:11Z | |
dc.date.available | 2023-10-26T15:56:11Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Rojas, Á., Lara-Romero, C., Muñoz Hernández, R., Gato, S., Ampuero Herrojo, J. y Romero Gómez, M. (2022). Emerging pharmacological treatment options for MAFLD. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/20420188221142452. | |
dc.identifier.issn | 2042-0188 | es |
dc.identifier.uri | https://hdl.handle.net/11441/149930 | |
dc.description.abstract | Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and
incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight,
type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension,
hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk,
increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis,
necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and
liver decompensations including hepatocellular carcinoma development. The limitation of
approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent
pathways and targets with evidence results in phase II/III iclinical trials. | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.relation.ispartof | Therapeutic Advances in Endocrinology and Metabolism. | |
dc.rights | Attribution-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nd/4.0/ | * |
dc.subject | Clinical trial | es |
dc.subject | Onalcoholic fatty liver disease | es |
dc.subject | Pathways | es |
dc.subject | Review | es |
dc.subject | Therapeutics | es |
dc.title | Emerging pharmacological treatment options for MAFLD | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Fisiología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Instituto de Biomedicina de Sevilla (IBIS) | |
dc.relation.publisherversion | https://journals.sagepub.com/doi/10.1177/20420188221142452 | es |
dc.identifier.doi | 10.1177/20420188221142452 | es |
dc.journaltitle | Therapeutic Advances in Endocrinology and Metabolism | es |